England's NHS to Offer Enhertu for HER2-Low Advanced Breast Cancer

About 1,000 women a year in England with HER2-low advanced breast cancer — spread cancer with low HER2 protein — can receive Enhertu on the NHS. NICE recommended routine use on 17 September 2026 after a price deal between ministers, NHS England, AstraZeneca and Daiichi Sankyo. Wales and Northern Ireland are likely to follow; Scotland has offered it since December 2023.